Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News XORTX Therapeutics Inc XRTX


Primary Symbol: V.XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

Recent & Breaking News (TSXV:XRTX)

XORTX Announces Publication of Key Research in ADPKD

GlobeNewswire 4 days ago

XORTX Welcomes New Member to the Board of Directors

GlobeNewswire April 8, 2024

XORTX Announces Participation in Spring 2024 Investor Conferences

GlobeNewswire April 8, 2024

XORTX Announces New Clinical Advisory Board Member

GlobeNewswire March 27, 2024

XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial

TheNewsWire March 19, 2024

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

GlobeNewswire March 19, 2024

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

GlobeNewswire March 11, 2024

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

GlobeNewswire March 4, 2024

XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units

GlobeNewswire February 15, 2024

XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units

GlobeNewswire February 1, 2024

XORTX Announces $2 Million Public Offering

GlobeNewswire January 15, 2024

XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

GlobeNewswire January 3, 2024

XORTX Welcomes New Member to the Board of Directors

GlobeNewswire January 2, 2024

XORTX Announces US ATM Offering

GlobeNewswire November 30, 2023

XORTX Meets Nasdaq Continued Listing Requirements

GlobeNewswire November 29, 2023

XORTX Clarifies Timing for Share Consolidation

GlobeNewswire November 10, 2023

XORTX Announces Share Consolidation

GlobeNewswire November 8, 2023

XORTX Sponsored Study Presented at the American Society of Nephrology - Kidney Week 2023

GlobeNewswire November 2, 2023

XORTX Announces Results of Special Meeting of Shareholders

GlobeNewswire October 27, 2023

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

GlobeNewswire October 25, 2023